BRISTOL-MYERS SQUIBB COMPANY Securities Borrowed, Fair Value of Collateral
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Securities Borrowed, Fair Value of Collateral of $1.20 billion as of 2021-12-31, per its 10-K filed 2022-02-09.
Discontinued › Notes
us-gaap:SecuritiesBorrowedFairValueOfCollateral · last filed 2022-02-09
- 2021-12-31: Securities Borrowed, Fair Value of Collateral $1.20B.
- 2020-12-31: Securities Borrowed, Fair Value of Collateral $1.20B.
- 2019-12-31: Securities Borrowed, Fair Value of Collateral $850.00M.
- 2018-12-31: Securities Borrowed, Fair Value of Collateral $1.00B.
| Period end | Securities Borrowed, Fair Value of Collateral |
|---|---|
| 2021-12-31 | $1.20B 10-K · filed 2022-02-09 |
| 2020-12-31 | $1.20B 10-K · filed 2021-02-10 |
| 2019-12-31 | $850.00M 10-K · filed 2020-02-24 |
| 2018-12-31 | $1.00B 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |